Want to see SCYX full AI Analyst Report?
SCYX Stock Chart & Stats
$0.66
-$0.06(-4.73%)
At close: 4:00 PM EST
$0.66
-$0.06(-4.73%)
Day’s Range― - ―
52-Week Range$3.68 - $10.48
Previous CloseN/A
Volume100.07K
Average Volume (3M)612.75K
Market Cap
$40.42M
Enterprise Value-$10.71M
Total Cash (Recent Filing)$59.26M
Total Debt (Recent Filing)$2.06M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Aug 17, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.58
Shares Outstanding9,930,329
10 Day Avg. Volume689,890
30 Day Avg. Volume612,753
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market Cap-0.27
Enterprise Value/Revenue-0.53
Enterprise Value/Gross Profit-0.53
Enterprise Value/Ebitda0.44
Forecast
1Y Price Target
$32.00Price Target Upside4748.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.99
Revenue Forecast (FY)$1.17M
Bulls Say, Bears Say
Bulls Say
Pipeline Expansion: SCY-770 (Phase 2, ADPKD)Acquiring SCY-770 meaningfully diversifies SCYNEXIS beyond antifungals into a rare-disease, potentially disease-modifying program with orphan designation and an FDA-endorsed surrogate endpoint, which can drive durable value via an accelerated path and long-term commercial exclusivity.
Extended Cash Runway From $40M PIPEThe strategic $40M financing materially reduces near-term funding pressure, providing multi-year runway to initiate Phase 2 for SCY-770 and advance antifungal programs. Backing by specialist investors and management participation improves financing credibility and execution optionality.
Conservative Recent Leverage On Balance SheetRelatively low debt gives the company structural flexibility to fund R&D and absorb operational volatility without large interest burdens. For a development-stage biotech, limited leverage reduces refinancing risk and preserves optionality to execute clinical milestones and partnerships.
Bears Say
Persistent Negative Cash GenerationOngoing negative operating and free cash flow means the company must rely on external financing or partner receipts to fund trials and commercialization. This structural cash burn elevates dilution and execution risk if clinical timelines or partner payments slip.
Volatile Revenue And Steep Recent LossesHighly lumpy revenue and a swing from prior profitability to material losses show weak earnings durability. Dependence on milestone/royalty recognition and inconsistent product revenue undermines predictable cash flow and complicates long-term planning and resource allocation.
Material Dilution And Expanded Share CapacitySignificant increases in authorized shares, incentive plan capacity and broad resale registration create structural dilution risk. Outstanding warrants and registered resale can expand share supply over time, reducing per-share economics and pressuring returns for existing holders.
SCYNEXIS News
SCYX FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest stock price was $3.68 and its highest was $10.48 in the past 12 months.
What is SCYNEXIS’s market cap?
SCYNEXIS’s market cap is $40.42M.
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is Aug 17, 2026 which is in 47 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on May 11, 2026. The company reported -$3.36 earnings per share for the quarter, missing the consensus estimate of -$0.987 by -$2.373.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -0.51.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 9,930,329 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of -$3.36 in its last earnings report, missing expectations of -$0.987. Following the earnings report the stock price went down -5.34%.
Which hedge fund is a major shareholder of SCYNEXIS?
Currently, no hedge funds are holding shares in SCYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SCYNEXIS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.00 (4748.48% Upside)
$32.00 (4748.48% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 11.1%
Last 30 Days ▼ 11.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.87%
12-Months-Change
Fundamentals
Return on Equity
-57.16%
Trailing 12-Months
Asset Growth
14.30%
Trailing 12-Months
Company Description
SCYNEXIS
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
SCYX Stock 12 Month Forecast
Average Price Target
$32.00
▲(4748.48% Upside)
Technical Analysis
Rockwell Med
―
TherapeuticsMD
―
Aytu BioScience
―
Cumberland Pharmaceuticals
―
IM Cannabis Corp
―
Ownership Overview
24.07% Insiders
19.48% Mutual Funds
― Other Institutional Investors
39.79% Public Companies and
Individual Investors